Novel Sjogren's Drug Passes First Phase III Test

Amgen's investigational CD40L antagonist dazodalibep demonstrated statistically significant efficacy and safety in a 48-week phase III trial for Sjögren's disease, showing clinically meaningful reductions in disease activity scores compared to placebo. The drug, a fusion protein distinct from monoclonal antibodies, is on track for likely approval pending completion of a second phase III trial.

This Wire brief sits within Fusion42's coverage of Biotech.